Literature DB >> 6404473

Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis.

H M Falck, C P Maury, A M Teppo, O Wegelius.   

Abstract

The importance of serum amyloid A protein in the progression of renal failure was studied over three years in 28 patients with secondary (amyloid A type) amyloidosis predominantly due to rheumatoid arthritis. Creatinine clearance, the amount of protein in the urine, and serum amyloid A and C-reactive protein concentrations were determined regularly. Linear regression analysis showed a close correlation between the change in creatinine clearance each year and both serum amyloid A concentrations (20 patients: r= -0.83, p less than 0.001) and C-reactive protein concentrations (28 patients: r= -0.80, p less than 0.001). The correlation between serum amyloid A and C-reactive protein concentrations was also significant (317 parallel measurements: r=0.81, p less than 0.001). These findings suggest that monitoring serum amyloid A or C-reactive protein concentrations is valuable in assessing the prognosis in secondary amyloidosis and that therapeutic measures that lower serum amyloid A concentrations may reduce the formation of amyloid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404473      PMCID: PMC1547845          DOI: 10.1136/bmj.286.6375.1391

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis.

Authors:  C P Maury; A M Teppo
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

2.  Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin.

Authors:  R P Linke; J D Sipe; P S Pollock; T F Ignaczak; G G Glenner
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils.

Authors:  M Levin; E C Franklin; B Frangione; M Pras
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

4.  Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C P Maury; A M Teppo; O Wegelius
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

5.  A serum component related to nonimmunoglobulin amyloid protein AS, a possible precursor of the fibrils.

Authors:  G Husby; J B Natvig
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

6.  The influence of glomerular and interstitial factors on the serum creatinine concentration in renal amyloidosis.

Authors:  S Mackensen; K E Grund; R Bader; A Bohle
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-09-28

7.  Variation with age and disease of an amyloid A protein-related serum component.

Authors:  C J Rosenthal; E C Franklin
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

8.  Morphologic and clinical correlates in renal amyloidosis.

Authors:  S H Dikman; J Churg; T Kahn
Journal:  Hum Pathol       Date:  1981-02       Impact factor: 3.466

9.  Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis.

Authors:  O Wegelius; A M Teppo; C P Maury
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-27

10.  A family study of leprosy: subcutaneous amyloid deposits and humoral immune responses.

Authors:  A G Wangel; O Wegelius; A E Dyrting
Journal:  Int J Lepr Other Mycobact Dis       Date:  1982-03
View more
  11 in total

Review 1.  beta 2-Microglobulin amyloidosis. A systemic amyloid disease affecting primarily synovium and bone in long-term dialysis patients.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature.

Authors:  Adarsh Babu; Helen Lachmann; Tom Pickett; Preetham Boddana; Linmarie Ludeman
Journal:  CEN Case Rep       Date:  2013-08-09

3.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 4.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

5.  Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis.

Authors:  Y Okuda; K Takasugi; T Oyama; H Oyama; S Nanba; T Miyamoto
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

6.  Systemic AA amyloidosis induced by liver cell adenoma.

Authors:  P Fievet; H Sevestre; M Boudjelal; L H Noel; F Kemeny; D Franco; J Delamarre; J P Capron
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

7.  Serologic evaluation of clinical and subclinical secondary hepatic amyloidosis in rhesus macaques (Macaca mulatta).

Authors:  Jamus G MacGuire; Kari L Christe; JoAnn L Yee; Alexis L Kalman-Bowlus; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

8.  Measurement of serum amyloid A protein concentrations as test of renal allograft rejection in patients with initially non-functioning grafts.

Authors:  C P Maury; A M Teppo; J Ahonen; E von Willebrand
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-04

9.  Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency.

Authors:  M Ahlmen; J Ahlmen; C Svalander; H Bucht
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

10.  Diagnosis of amyloidosis and differentiation from chronic, idiopathic enterocolitis in rhesus (Macaca mulatta) and pig-tailed (M. nemestrina) macaques.

Authors:  Kelly A Rice; Edward S Chen; Kelly A Metcalf Pate; Eric K Hutchinson; Robert J Adams
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.